App-Quantinova.ai

Correlation between mismatch repair deficiency (MMRd), microsatellite instability (MSI) and survival in MAGIC.

Elizabeth Catherine Smyth - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Mismatch repair deficiency

N/A

Assessment of preoperative liver function in patients with hepatocellular carcinoma: The albumin-indocyanine green evaluation (ALICE) grade.

Takashi Kokudo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-) receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP).

Sandrine J. Faivre - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

LY2157299

Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study.

Bruno Sangro - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Nivolumab

mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomized phase II trials comparing nintedanib versus sorafenib.

Tim Meyer - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Nintedanib

External validation of a prognostic score in patients (pts) with high-grade gastrointestinal neuroendocrine carcinomas (GI-NECs).

Angela Lamarca - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastrointestinal neuroendocrine carcinomas

N/A

Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: Second interim overall survival (OS) results from the RADIANT-4 study.

James C. Yao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroendocrine tumors

Somatostatin

Exploratory analysis of tumor growth rate (TGR) with lanreotide depot/autogel (LAN) in patients (pts) with neuroendocrine tumors (NETs) from the CLARINET study.

Martyn E. Caplin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroendocrine tumors

Lanreotide

RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation.

Susan M. Domchek - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

Rucaparib

Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy.

Andrea Wang-Gillam - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic pancreatic adenocarcinoma

5-fluorouracil + leucovorin

Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer: Results from the phase I/II CheckMate 032 study.

Padmanee Sharma - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

Nivolumab

Safety and efficacy of durvalumab (MEDI4736), an anti-PD-L1 antibody, in urothelial bladder cancer.

Christophe Massard - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Durvalumab

Overall survival in METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma

Toni K. Choueiri - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Cabozantinib

Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.

Bernard J. Escudier - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Nivolumab

First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).

Jose Manuel Ruiz Morales - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Pazopanib

Updated efficacy from IMvigor210: Atezolizumab in platinum treated locally advanced/metastatic urothelial carcinoma (mUC).

Robert Dreicer - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

Atezolizumab

Circulating tumor cells (CTC) and HER-2 status on CTC and primary tumor in urothelial cancer (UC) patients refractory to platinum based chemotherapy.

Maria De Santis - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

FIESTA: a Phase Ib and pharmacokinetic trial of AZD4547 in combination with gemcitabine and cisplatin.

Robert Hugh Jones - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Gemcitabine

Patterns of chemotherapy administration in bladder preservation therapy (BPT) for muscle-invasive bladder cancer (MIBC).

Tracy Lynn Rose - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

Carboplatin AUC 10 in metastatic seminoma: Role of early PET scanning to reduce the amount of treatment while maintaining outcomeA phase 2 study (CarPET).

Jonathan Shamash - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Seminoma

Carboplatin

Filters

45280 Abstracts